Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer

Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer

US Patent 11319376 · Granted May 3, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Calcitonin gene-related peptide (CGRP) antagonist antibodies2023
Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)2022
Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CT2022
Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)2022
Anti-OX40 antibodies and methods of activating OX402022
Methods and compositions for treating tumor diseases2021
Compositions and methods relating to anti-IGF-1 receptor antibodies2018
Compositions and methods relating to anti-IGF-1 receptor antibodies2014
Compositions and methods relating to anti-IGF-1 receptor antibodies2013
Compositions and methods relating to anti-IGF-1 receptor antibodies2012
Compositions and methods relating to anti IGF-1 receptor antibodies2011
Osteoprotegerin2009